Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96FM1
UPID:
PGAP3_HUMAN
Alternative names:
COS16 homolog; Gene coamplified with ERBB2 protein; PER1-like domain-containing protein 1
Alternative UPACC:
Q96FM1; B4DGK7; Q86Z03; Q8NBJ8
Background:
Post-GPI attachment to proteins factor 3, also known as COS16 homolog, Gene coamplified with ERBB2 protein, and PER1-like domain-containing protein 1, plays a crucial role in the lipid remodeling steps of GPI-anchor maturation. This process is essential for generating 2 saturated fatty chains at the sn-2 position of GPI-anchors proteins, facilitating the correct anchoring of proteins to the cell membrane.
Therapeutic significance:
The protein's involvement in Hyperphosphatasia with impaired intellectual development syndrome 4, a neurologic disorder characterized by developmental delay and severe intellectual disability, highlights its potential as a target for therapeutic intervention. Understanding the role of Post-GPI attachment to proteins factor 3 could open doors to potential therapeutic strategies.